PL1838301T3 - Użycie resiniferatotoksyny (RTX) dla wytwarzania środka leczącego stany bólowe - Google Patents

Użycie resiniferatotoksyny (RTX) dla wytwarzania środka leczącego stany bólowe

Info

Publication number
PL1838301T3
PL1838301T3 PL04802396T PL04802396T PL1838301T3 PL 1838301 T3 PL1838301 T3 PL 1838301T3 PL 04802396 T PL04802396 T PL 04802396T PL 04802396 T PL04802396 T PL 04802396T PL 1838301 T3 PL1838301 T3 PL 1838301T3
Authority
PL
Poland
Prior art keywords
resiniferatoxin
rtx
pain
agent
preparation
Prior art date
Application number
PL04802396T
Other languages
English (en)
Polish (pl)
Inventor
Dominik Meyer
Original Assignee
Mestex Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mestex Ag filed Critical Mestex Ag
Publication of PL1838301T3 publication Critical patent/PL1838301T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL04802396T 2004-12-28 2004-12-28 Użycie resiniferatotoksyny (RTX) dla wytwarzania środka leczącego stany bólowe PL1838301T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CH2004/000756 WO2006069451A1 (de) 2004-12-28 2004-12-28 Verwendung von resiniferatoxin (rtx) für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels
EP04802396.4A EP1838301B1 (de) 2004-12-28 2004-12-28 Verwendung von resiniferatoxin (rtx) für die herstellung eines mittels zur behandlung von schmerzen

Publications (1)

Publication Number Publication Date
PL1838301T3 true PL1838301T3 (pl) 2015-08-31

Family

ID=34959549

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04802396T PL1838301T3 (pl) 2004-12-28 2004-12-28 Użycie resiniferatotoksyny (RTX) dla wytwarzania środka leczącego stany bólowe

Country Status (8)

Country Link
US (2) US20080139641A1 (enExample)
EP (1) EP1838301B1 (enExample)
JP (1) JP5775246B2 (enExample)
CA (1) CA2594202C (enExample)
DK (1) DK1838301T3 (enExample)
ES (1) ES2533256T3 (enExample)
PL (1) PL1838301T3 (enExample)
WO (1) WO2006069451A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057930A2 (en) 2006-11-02 2008-05-15 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with retinoic acid receptor agonists
US8697155B2 (en) * 2008-07-22 2014-04-15 Mayo Foundation For Medical Education And Research Treatment of obesity and related disorders
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
EP3269371A1 (en) 2011-06-10 2018-01-17 Queen Mary University of London Artemisinin and its derivatives for use in the treatment of myocardial infarction or coronary heart disease
US20150190509A1 (en) * 2012-08-03 2015-07-09 Mestex Ag Resiniferatoxin solution
US9603831B2 (en) 2012-12-12 2017-03-28 Queen Mary & Westfield College, University Of London Artemisinin and its derivatives for use in the treatment of kidney disease
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
US11000490B2 (en) 2016-11-02 2021-05-11 Centrexion Therapeutics Corporation Stable aqueous capsaicin injectable formulations and medical uses thereof
US11400136B2 (en) * 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
WO2019018769A1 (en) 2017-07-20 2019-01-24 Centrexion Therapeutics Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE
US20190076396A1 (en) * 2017-09-11 2019-03-14 Sorrento Therapeutics, Inc. Formulation of resiniferatoxin
CN113490745A (zh) * 2018-12-21 2021-10-08 索伦托药业有限公司 神经周施用树脂毒素治疗适应不良性疼痛
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
WO2020154261A1 (en) * 2019-01-22 2020-07-30 Sorrento Therapeutics, Inc. Method for treating osteoarthritis pain by administering resiniferatoxin
CN110123833A (zh) * 2019-05-31 2019-08-16 龚啸元 一种关节镜手术用灌流液及其制备方法
ES3004508T3 (en) * 2020-04-15 2025-03-12 Gruenenthal Gmbh Resiniferatoxin compositions
US20250228765A1 (en) 2024-01-15 2025-07-17 Gruenenthal Gmbh Treating knee joint pain by injecting resiniferatoxin at ultra low doses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3104085A (en) 1960-07-18 1963-09-17 Ind Paper Log Inc Compressed fibrous articles
US4939149A (en) * 1988-10-24 1990-07-03 The United States Of America As Represented By The Department Of Health And Human Services Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization
US4997853A (en) * 1988-12-02 1991-03-05 Galenpharma, Inc. Method and compositions utilizing capsaicin as an external analgesic
AU5744490A (en) * 1989-05-15 1990-12-18 Afferon Corporation Composition and method for neural desensitization
EP1201241B8 (en) 1997-03-13 2010-10-27 James N. Campbell Compositions containing capsaicin or capsaicin analogues and an anesthetic
GB9711962D0 (en) 1997-06-10 1997-08-06 Reckitt & Colmann Prod Ltd Therapeutically active compositions
AU2001297015A1 (en) * 2000-10-15 2002-04-29 Ortho-Mcneil Pharmaceutical, Inc. Improved ligand binding assays for vanilloid receptors
CA2435418A1 (en) * 2001-01-24 2002-08-01 Mestex Ag Use of neurotoxic substances in producing a medicament for treating joint pains
CA2442049C (en) 2001-03-22 2010-06-01 Michael J. Iadarola Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist
US20030104085A1 (en) * 2001-12-05 2003-06-05 Yeomans David C. Methods and compositions for treating back pain
NZ540769A (en) 2002-12-18 2009-03-31 Algorx Pharmaceuticals Inc Administration of capsaicinoids for the treatment of pain
WO2006066419A1 (de) * 2004-12-22 2006-06-29 Mestex Ag Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels

Also Published As

Publication number Publication date
EP1838301B1 (de) 2015-01-28
ES2533256T3 (es) 2015-04-08
WO2006069451A1 (de) 2006-07-06
US20100196281A1 (en) 2010-08-05
CA2594202C (en) 2013-12-03
DK1838301T3 (en) 2015-04-27
EP1838301A1 (de) 2007-10-03
JP2008525504A (ja) 2008-07-17
US9044452B2 (en) 2015-06-02
CA2594202A1 (en) 2006-07-06
US20080139641A1 (en) 2008-06-12
JP5775246B2 (ja) 2015-09-09

Similar Documents

Publication Publication Date Title
SG118421A1 (en) Apparatus for the manufacture of medical devices
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
AP2007004157A0 (en) N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain
EP1809265A4 (en) Methods for the treatment of synucleinopathies
IL213897A0 (en) Ultrasound contrast agent dosage formulation
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
EP1626692A4 (en) COMPOUNDS FOR TREATING FLAVIVIRUS INFECTIONS
IL187405A0 (en) Methods and compositions for the treatment of pain
IL178827A0 (en) Use of reboxetine for the treatment of pain
IL183893A0 (en) Pharmaceutical compositions for the treatment of cellulite
IL169171A0 (en) Manufacturing apparatus for the packaging of medical devices including integrated lancets
PL1740204T3 (pl) Lecznicze zastosowanie alfa-mannozydazy
EP1867640A4 (en) MEANS FOR TREATING SOLID TUMORS
IL179337A0 (en) Pharmaceutical compositions for the treatment of pruritus
GB0415181D0 (en) Compounds for use in the treatment of infection
EP1750698A4 (en) 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES
IL178907A0 (en) Use of sulglicotide for the treatment of mucositis
IL172101A0 (en) Use of indazole derivatives for the treatment of neuropathic pain
IL170706A0 (en) Use of atii antagonist for the treatment or prevention of metabolic syndrome
ZA200710476B (en) Methods and compositions for the treatment of pain
EP1900363A4 (en) THERAPEUTIC AGENT AGAINST PAIN
GB0412262D0 (en) Use of compounds for the treatment of pain
ZA200608015B (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
ZA200704859B (en) Pharmaceutical compositions for the treatment of cellulite
LT1740204T (lt) Medicininis alfa-manozidazės panaudojimas